Market & RegulationInvestment · £500m
UK Sovereign AI Fund backs £500m drug discovery raise
Siftedhigh confidence
Why it matters
- →Sovereign funds entering drug discovery signals state-level prioritization of AI for scientific breakthroughs.
- →£500m raises the bar for capital requirements in early-stage AI-biotech startups.
- →Validates long-horizon, high-risk AI applications as critical national infrastructure.
The UK Sovereign AI Fund is currently in talks to lead a £500 million funding round for an early-stage startup specializing in AI-based drug discovery. This significant investment highlights the growing intersection between national strategic interests and advanced biotechnology, as governments seek to secure leadership in scientific innovation through direct capital deployment. The deal underscores a trend where sovereign wealth entities are actively backing deep-tech ventures that combine artificial intelligence with complex scientific challenges.
Read originalMore from Sifted
More in Market & Regulation
Market & Regulationother
CRB Questions Phonorecords V Settlement Independence
The Copyright Royalty Board is refusing to rubber-stamp the Phonorecords V Subpart B settlement, demanding proof that the negotiated rates reflect true arm's-length bargaining. Judges are specifically probing whether common corporate ownership between major publishers and record labels invalidates the 'willing buyer/willing seller' standard, while also questioning why inflation adjustments were excluded from the base rate. This intervention signals a rigorous review of who actually sat at the negotiating table and whether independent voices were sidelined. It sets a precedent that statutory rates cannot simply be imposed via private deals among industry giants without transparent economic justification.
Music Tech Policy
© TechCrunch AIInvestment · $100M
Market & Regulationbusiness
Vantora raises $100M for proprietary physical AI startups
Vantora’s $100M raise signals a pivot from open startup incubation to building proprietary AI ventures exclusively for corporate partners like Porsche and J.B. Hunt. This model allows companies to retain sovereignty over sensitive physical AI applications, such as retrofitting industrial hardware for autonomy, without exposing intellectual property to competitors. By shifting to a 'proprietary M&A pipeline,' Vantora unlocks high-value use cases that were previously too strategic to commercialize broadly. It represents a growing trend where enterprises prefer internal AI development over external vendor solutions for critical infrastructure.
TechCrunch AI
© TechCrunch AIMarket & Regulationbusiness
Anthropic hires Accenture for embedded AI safety evaluation
Anthropic is breaking from the academic norm by embedding Accenture’s Faculty division directly into its labs to red-team models and assess alignment. This $1 billion five-year partnership signals a shift toward corporate-grade, independent oversight rather than relying solely on research nonprofits like METR. The move leverages Accenture’s enterprise deployment experience to create a functional independence that pure academic partners lack. It marks the first concrete step in Dario Amodei’s vision for embedded evaluators, prioritizing verifiable accountability over theoretical safety research.
TechCrunch AI